The investor call is scheduled for 8:30 AM Beijing Time on August 19, which corresponds to 8:30 PM U.S. Eastern Time on August 18. Everest Medicines will provide a dedicated webcast link for the Chinese-language session, alongside international dial-in numbers covering the U.S., UK, Hong Kong, Taiwan, and Singapore. The session will feature simultaneous English interpretation via a separate Zoom-based registration.

Everest Medicines currently maintains a broad therapeutic focus, including autoimmune, ophthalmology, and critical care treatments. The upcoming call serves as a platform for management to detail the company's progress with its proprietary mRNA platform and ongoing pipeline development. Interested parties can access the conference using the passcode 834993.